Otolith Labs is a Washington, D.C. medical device company building the first wearable to treat vertigo, motion sickness and virtual-reality sickness. Its patented non-invasive Vestibular Resonance Therapy (nVRT) uses precisely tuned bone-conduction vibrations to interact with the motion sensors of the inner ear, quieting the faulty balance signals that cause dizziness. The head-worn OtoBand has been tested on hundreds of subjects, carries an FDA Breakthrough Device Designation, and is pursuing FDA clearance through the De Novo pathway.
XII Medical is a Union City, California medical device company building a minimally invasive neuromodulation therapy for obstructive sleep apnea (OSA). Founded in 2017 and led by CEO Garrett Schwab, the company is developing an implantable platform designed to be smaller, more flexible and easier to implant than existing nerve-stimulation systems - an alternative for the estimated 425 million people worldwide with moderate-to-severe OSA who struggle with CPAP masks. Backed by Cleveland Clinic, Ajax Health, Omega Funds and Intuitive Ventures, XII Medical closed a $45M Series B in August 2024 to fund product and clinical development.
Scott Kokones is co-founder and CEO of Enspire DBS Therapy, a Cleveland Clinic portfolio company building an implantable deep brain stimulation system paired with physical rehab to restore arm function in stroke survivors. He is running the RESTORE pivotal trial after the EDEN proof-of-concept study, having raised $27.9M total including a $17.6M Series B in 2023 and a $10.3M Series B1 in January 2026. Alongside Enspire he is a general partner at Guide Medical Ventures and a co-founder of Qr8 Health and CardioSolv Ablation Technologies. His earlier career runs through Intelect Medical, Boston Scientific, Enpath Medical, and Medtronic.
NeuroBionics is a Boston-area neurotechnology company spun out of more than a decade of MIT research. It builds hair-thin, flexible bioelectronic fibers that reach neural targets through the body's blood vessels instead of open surgery. Its lead device, evStim, aims to deliver deep brain and peripheral nerve stimulation endovascularly, potentially widening access to neuromodulation therapy for conditions like Parkinson's disease, epilepsy, chronic pain, and depression.
Samphire Neuroscience is a London-based neurotechnology company building drug-free, hormone-free wearables for women's health. Its flagship product, Nettle, is a headband that uses transcranial direct current stimulation (tDCS) to gently modulate the brain regions tied to mood and pain, worn 20 minutes a day in the run-up to menstruation. Marketed as the first EU-cleared (CE-certified) neuromodulation device for women's health, Nettle targets PMS, PMDD, menstrual pain and related hormonal conditions. Founded in 2021 by neuroscientist Emilė Radytė and IP lawyer Alex Cook, the company has raised roughly $7.77M across pre-seed, seed and Series A rounds.